Page 14 - Read Online

Page 4 of 13 Jahansouz et al. Mini-invasive Surg 2021;5:1 I http://dx.doi.org/10.20517/2574-1225.2020.82

Follow Up 7.1 months median 385 (67-884) days range 3 to 23 months median 11 (3-19) 3 months 30 (1-79) months median 39.5 (10.5-65.3) months median 26 months 8 weeks 14.4 (± 17.4) not recorded

Recurrence (n) 7 0 0 1 1 benign, 1 malignant 1 1 benign, 2 malignant (10.3%) 0 6% (distant in 2%) not recorded

Conversions/ Complications 9 conversions, 34 complications 0 conversions; 7 (9%) Intraop; 15 (19%) Postop 3 (10%) with lap assistance; 25% morbidity 1 (3%) conversion; 14% morbidity 10% conversion; 25% morbidity 0% conversion; 9.6% 1 benign complication 3 (4%) peritoneal entries w/2 loop ileostomies; 3 (4%) postop 22% complication 0% conversion; 0% complications 76% POD 0, 4% peritoneal entry, 2% abdominal assista

Length of Stay (days) 1.9 Median 3.4 (range 1-21) 2.5 (± 2.0) 1 (1-23) 1.5 Median 3 (2-7) median 1 (0-6) 3.9 (2-26) 2.7 (± 1.4) 28% POD 1, 20% POD 2 18) hours

Margins Positive (n) 12 (4 additional fragmented) 3 (4%) 1 (3%) 6 (16%) 5 (18%) 3.2% 5 (6.7%) 0 benign, 5 malignant (20%) 14 (7%); 9 (5%) fragmentation 2 (9.5%)

Defect Closure 40 (53%) closed, 35 (47%) 32 (100%) 27 (73%) 28 (100%) 31 (100%) 69 (92%) 1 32 (100%) 25 (100%) 188 (94%)

- open
Tumor Size (cm) 3.1 3.9 (± 1.6) 3.0 (± 2.0) Median 18 cm 2 benign 5 (1.2-11.5); malignant 4.3 (1.2-9.5) 2.4 (1-5) 3.2 (± 3.1) 14.5 (±14.4) cm 2 1.1 (± 0.5) 2.9 (± 1.5) 17 (2.1-55.0) 100% cm 2

Tumor Distance from AV (cm) 6.4 (± 2.3) 4.0 (± 3.0) median 7 (0-19) from dentate line not reported 9.5 (6-15) median 10 5.6 ± 1.5 8.4 (± 1.6) 7.2 (± 3.3) 7.8 (± 2.3)

7.6 (6-16)
Operative Time (min) 76 median 77 (25-245) 123 (± 62) median 64 (17-211) all cases < 60 min not reported 76 (± 36.1) 69 (35- 210) 61.3 (± 25.5) 69.5 (± 37.9) 100 (± 55)
Table 1. Outcomes of selected cases following laparoscopic TAMIS

Indications (Pathology) 152 benign, 209 malignant, 29 others 42 benign, 32 malignant, 1 carcinoid 10 benign, 22 malignant 23 benign, 13 malignant 17 benign, 11 malignant 17 benign, 10 malignant, 4 others 59 benign, 17 malignant 15 benign, 12 malignant, 5 others 3 benign, 22 malignant 90 benign, 110 malignant 15 benign, 4 malignant, 2 others

Patients (n) 390 75 37 28 31 75 32 25 200 21

Transanal Port SILS GelPOINT Path, 32 GelPOINT Path Long Channel, SILS SILS GelPOINT Path or SILS GelPOINT Path or SILS GelPOINT Path or SILS SILS GelPOINT Path or SILS GelPOINT Path Mean unless otherwise stated in column header

Author, Publication Martin-Perez et al. [13] , Multiple Tech Coloproctol 2014 Hahnloser et al. [18] , Colorectal Dis 2014 McLemore et al. [17] , Am J Surg 2014 Schiphorst et al. [28] , DCR 2014 Sumrien et al. [29] , Anticancer Res 2016 Quaresima et al. [25] , JSLS 2016 Keller et al. [21] , J Am Coll Surg 2016 García-Flórez et al. [26] , GelPOINT Path Surg Innov 2017 Chen et al. [27] , World J Gastrointest Oncol 2018